

Table 4. List of seed treatments used on corn hybrids entered in the 2013 UW corn trials.

Seed Trt	Brand Name	Treatment Mix			Grain yield †		Forage yield †	
		Fungicide	Insecticide	Nematicide	N	(bu/A)	N	(T/A)
1		Captan					81	-0.05
2		Maxim			12		18	
3		Untreated			210	-2.0	30	
7		Poncho250			12			
37	CruiserExtremePak250	ApronXL+Dynasty+MaximXL Cruiser			360	-5.2	237	* 0.32
43		MaximXL Cruiser			255	-4.1	51	* 0.50
53		Poncho500 VOTiVO			278	3.1	123	-0.21
55		ApronXL+Maxim Poncho250					90	* 0.09
97		Dynasty+MaximXL Cruiser250			387	-0.9	132	-0.33
113		Dynasty+MaximXL Lorsban					49	
121	Avicta Complete Corn	ApronXL+Dynasty+MaximXL Cruiser Avicta			207	-6.0	93	-0.29
128	Maxim Quattro	Apron+Dynasty+Maxim+TBZ			254	* 5.8	174	* 0.12
132	Acceleron IC-609	Poncho			117	* 3.2	18	
133	Maxim Quattro + Cruiser250	Apron+Dynasty+Maxim+TBZ Cruiser250			96	-3.8	9	
136	Acceleron+Poncho500+VOTiVO	Apron+Stratego+Vortex Poncho500 VOTiVO			570	* 0.6	369	* 0.03
138		Allegiance+Trilex+Vortex Poncho500 VOTiVO			155	-1.4	81	-0.13
147	Acceleron+Poncho250+VOTiVO	Apron+Stratego+Vortex Poncho250 VOTiVO			57	-1.4		
149	CruiserMaxx Corn250	Cruiser 5FS Maxim Quattro			545	-1.7	273	* 0.24
150		Poncho1250+VOTiVO			426	* 4.4	138	* 0.23
151	Acceleron 250	Apron+Stratego+Vortex Poncho250			599	-2.0	80	-0.33
152	X-Cell ST	None			75	* 5.1		
157		Allegiance+Trilex+Vortex Poncho250 VOTiVO			135	-2.4	72	-0.53
158	Acceleron 250+Wuxal Terios Zn+	Apron+Stratego+Vortex Poncho250 Wuxal Terios Zn+			105	* 6.6	69	-0.40
159		Dynasty+Maxim Quattro Cruiser250 Vortex			72	* 6.5	6	
160		Poncho250+Zn			81	-8.7		
161	Maxim Quattro+Poncho250	Apron+Dynasty+Maxim+TBZ Poncho250			9			
162	Maxim Quattro+Quickroots	Apron+Dynasty+Maxim+TBZ Quickroots			48		27	
164	CruiserMaxx Corn250+Quickroots	Cruiser 5FS Maxim Quattro Quickroots			77	-8.9	84	-0.02
		LSD(0.10)				7.1		0.47

† Grain and forage yield are calculated in relation to the trial mean. A minimum of 50 plots was required before inclusion in the analysis.

* Treatments that performed statistically similar to the highest treatment in the trial.